Heparin-binding epidermal growth factor-like growth factor and hepatocyte growth factor inhibit cholestatic liver injury in mice through different mechanisms.

PMID 27779646 ↗2016Reported benefit

Heparin-binding epidermal growth factor-like growth factor and hepatocyte growth factor inhibit cholestatic liver injury in mice through different mechanisms.

MouseOtherC57BL/6Jmalen = Ad.LacZ day 3 n=9, day 14 n=15; Ad.HB-EGF day 3 n=11, day 1…intravenous, tail vein injectionadenoviral vector injected on day 0, immediately prior to bile duct ligation su…

Model: bile duct ligation-induced cholestatic liver injury

HB-EGF and HGF gene therapy, alone or in combination, reduced hepatocyte oncosis, apoptosis and cholestasis and promoted hepatocyte regeneration after bile duct ligation in mice. HB-EGF produced greater acute cytoprotective effects on serum transaminases, whereas HGF more potently inhibited liver f…

Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Heparin-binding epidermal growth factor-like growth factor and hepatocyte growth factor inhibit cholestatic liver injury in mice through different mechanisms.

Evidence by therapy association

Heparin-binding epidermal growth factor-like growth factor and hepatocyte growth factor inhibit cholestatic liver injury in mice through different mechanisms.